Detalles de la búsqueda
1.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Br J Clin Pharmacol
; 87(2): 598-611, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32520410
2.
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Circulation
; 135(4): 352-362, 2017 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-27986651
3.
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Br J Clin Pharmacol
; 76(1): 65-77, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23278647
4.
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Br J Clin Pharmacol
; 68(6): 928-35, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20002088
5.
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
J Am Heart Assoc
; 5(6)2016 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27287699
6.
A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.
Cardiovasc Ther
; 32(6): 297-301, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25256660
Resultados
1 -
6
de 6
1
Próxima >
>>